Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedSep 14, 2025
DataAggregated Company Financials
Companies61
  • 7D-7.7%
  • 3M51.8%
  • 1Y-24.7%
  • YTD-0.08%

Over the last 7 days, the Pharma industry has dropped 7.8%, driven by Curaleaf Holdings declining 16%. In contrast, Grown Rogue International has gained 12%. However, the industry is down 25% over the past year. As for the next few years, earnings are expected to grow by 59% per annum.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 14 Sep 2025CA$15.3bCA$11.2b-CA$2,034,635,474.5240.3x-7.5x1.4x
Tue, 12 Aug 2025CA$13.6bCA$11.7b-CA$2,533,797,497.3522.8x-5.4x1.2x
Thu, 10 Jul 2025CA$10.5bCA$11.7b-CA$2,541,044,068.9119.2x-4.1x0.9x
Sat, 07 Jun 2025CA$9.5bCA$11.7b-CA$2,523,071,804.7118x-3.8x0.8x
Mon, 05 May 2025CA$10.8bCA$11.9b-CA$2,504,572,218.8420.9x-4.3x0.9x
Wed, 02 Apr 2025CA$10.3bCA$12.3b-CA$2,631,360,614.3619.4x-3.9x0.8x
Fri, 28 Feb 2025CA$11.5bCA$12.3b-CA$2,223,991,819.0622.2x-5.2x0.9x
Sun, 26 Jan 2025CA$12.1bCA$12.1b-CA$2,410,157,394.2135.6x-5x1x
Tue, 24 Dec 2024CA$12.7bCA$12.1b-CA$2,414,726,587.7422.8x-5.3x1x
Thu, 21 Nov 2024CA$14.3bCA$12.0b-CA$2,672,739,880.9317x-5.3x1.2x
Sat, 19 Oct 2024CA$19.0bCA$11.8b-CA$2,708,707,823.9617.4x-7x1.6x
Mon, 16 Sep 2024CA$18.1bCA$11.6b-CA$2,703,089,761.5120.7x-6.7x1.6x
Wed, 14 Aug 2024CA$18.6bCA$11.7b-CA$2,767,314,339.1722.5x-6.7x1.6x
Fri, 12 Jul 2024CA$18.7bCA$11.7b-CA$3,179,115,064.6619.7x-5.9x1.6x
Sun, 09 Jun 2024CA$20.8bCA$11.8b-CA$2,756,296,099.6812.8x-7.5x1.8x
Tue, 07 May 2024CA$24.2bCA$11.8b-CA$3,417,258,262.8310.9x-7.1x2x
Thu, 04 Apr 2024CA$20.9bCA$10.4b-CA$3,522,094,811.729x-5.9x2x
Sat, 02 Mar 2024CA$21.0bCA$12.0b-CA$4,470,416,386.149.4x-4.7x1.8x
Mon, 29 Jan 2024CA$22.3bCA$12.3b-CA$6,748,442,370.009.6x-3.3x1.8x
Wed, 27 Dec 2023CA$17.1bCA$12.2b-CA$6,713,748,928.008.6x-2.5x1.4x
Fri, 24 Nov 2023CA$18.3bCA$12.5b-CA$6,838,777,984.007.1x-2.7x1.5x
Sun, 22 Oct 2023CA$17.3bCA$12.4b-CA$7,341,920,600.0012x-2.4x1.4x
Tue, 19 Sep 2023CA$22.3bCA$13.0b-CA$7,885,143,211.0014.6x-2.8x1.7x
Thu, 17 Aug 2023CA$13.7bCA$13.0b-CA$8,070,709,387.0010.8x-1.7x1.1x
Sat, 15 Jul 2023CA$15.9bCA$13.2b-CA$9,718,923,315.0012.4x-1.6x1.2x
Mon, 12 Jun 2023CA$14.8bCA$13.2b-CA$10,391,543,924.0010.4x-1.4x1.1x
Wed, 10 May 2023CA$16.2bCA$13.2b-CA$10,182,325,882.0010.2x-1.6x1.2x
Fri, 07 Apr 2023CA$15.5bCA$13.4b-CA$10,028,081,302.0011x-1.5x1.2x
Sun, 05 Mar 2023CA$20.0bCA$13.7b-CA$10,313,144,570.0010x-1.9x1.5x
Tue, 31 Jan 2023CA$19.2bCA$13.5b-CA$10,101,272,930.0014.3x-1.9x1.4x
Thu, 29 Dec 2022CA$18.8bCA$13.7b-CA$10,145,605,747.0014.9x-1.9x1.4x
Sat, 26 Nov 2022CA$30.1bCA$13.4b-CA$10,220,329,851.0010.9x-2.9x2.2x
Mon, 24 Oct 2022CA$27.8bCA$13.5b-CA$9,412,446,867.0011.1x-3x2.1x
Wed, 21 Sep 2022CA$27.6bCA$13.2b-CA$8,854,486,701.0012.1x-3.1x2.1x
Price to Earnings Ratio

-3.1x


Total Market Cap: CA$27.6bTotal Earnings: -CA$8,854,486,701.00Total Revenue: CA$13.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -4.1x202320242025
Current Industry PE
  • Investors are relatively neutral on the Canadian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 1.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 5.2% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?

CA Market0.93%
Healthcare-3.62%
Pharma-7.68%
Pharma-7.68%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GRIN Grown Rogue InternationalCA$0.6611.9%
+CA$17.5m		-25.0%PE41.1x
QNTM Quantum BioPharmaCA$23.8021.4%
+CA$16.0m		339.9%PB17.4x
EPIC 1CMCA$0.3950.0%
+CA$15.3m		25.8%PE26.3x
CPH Cipher PharmaceuticalsCA$16.402.4%
+CA$9.6m		4.4%PE24.7x
TRBR TRUBARCA$0.839.2%
+CA$7.5m		31.7%PS1.2x

Latest News

VREO
CA$0.65
Vireo Growth
7D
-3.0%
1Y
1.6%

With A 33% Price Drop For Vireo Growth Inc. (CSE:VREO) You'll Still Get What You Pay For

Sep 11
With A 33% Price Drop For Vireo Growth Inc. (CSE:VREO) You'll Still Get What You Pay For
EPIC
CA$0.39
1CM
7D
50.0%
1Y
25.8%

The Market Lifts 1CM Inc. (CSE:EPIC) Shares 44% But It Can Do More

Sep 10
The Market Lifts 1CM Inc. (CSE:EPIC) Shares 44% But It Can Do More
CL
CA$1.37
Cresco Labs
7D
-17.0%
1Y
-39.6%

Is Cresco Labs Inc. (CSE:CL) Trading At A 49% Discount?

Sep 06
Is Cresco Labs Inc. (CSE:CL) Trading At A 49% Discount?
OPTI
CA$0.26
Optimi Health
7D
13.0%
1Y
-13.3%
CPH
CA$16.40
Cipher Pharmaceuticals
7D
2.4%
1Y
4.4%

Expansion Into Canada Will Shape Global Dermatology Success

Cipher Pharmaceuticals' future P/E has risen sharply, indicating increased valuation relative to earnings, while the net profit margin is stable, resulting in no change to the consensus analyst price target at CA$17.90. What's in the News Cipher Pharmaceuticals is actively seeking accretive acquisitions and in-licensing opportunities, with a strategic focus on complementary U.S.-based assets and companies.
CURA
CA$3.33
Curaleaf Holdings
7D
-16.3%
1Y
-15.9%

Expanding German And Turkish Markets Will Unlock Global Opportunities

Despite steady revenue growth forecasts, Curaleaf Holdings' future P/E multiple has increased markedly, signaling a higher valuation relative to earnings and maintaining the consensus analyst price target at CA$3.83. Valuation Changes Summary of Valuation Changes for Curaleaf Holdings The Consensus Analyst Price Target remained effectively unchanged, at CA$3.83.
CRON
CA$3.49
Cronos Group
7D
0.3%
1Y
17.9%

GrowCo Capacity And Global Markets Will Unlock Potential

The Consensus Analyst Price Target for Cronos Group has increased to CA$3.95, primarily reflecting a notable rise in the company's Future P/E multiple despite stable revenue growth expectations. What's in the News President Trump is considering reclassifying marijuana as a less dangerous drug, which could ease restrictions and benefit cannabis companies such as Cronos Group (The Wall Street Journal).
VRNO
CA$1.59
Verano Holdings
7D
-14.1%
1Y
-63.3%

Cannabis Legalization In Key States Will Expand Retail Footprint

Verano Holdings’ consensus price target was revised downward, primarily reflecting a sharp increase in its future P/E multiple and stagnant discount rate, resulting in a lower fair value estimate of CA$4.21. What's in the News Verano Holdings launched a new bodega-style dispensary format at its Zen Leaf Phoenix-Cave Creek location in Arizona, aiming to modernize and enhance the cannabis retail experience.
WEED
CA$1.90
Canopy Growth
7D
-5.9%
1Y
-70.8%

Revenues Tell The Story For Canopy Growth Corporation (TSE:WEED) As Its Stock Soars 70%

Aug 30
Revenues Tell The Story For Canopy Growth Corporation (TSE:WEED) As Its Stock Soars 70%
TRUL
CA$9.59
Trulieve Cannabis
7D
-9.3%
1Y
-36.1%

Trulieve Cannabis Corp.'s (CSE:TRUL) Shares Climb 97% But Its Business Is Yet to Catch Up

Aug 29
Trulieve Cannabis Corp.'s (CSE:TRUL) Shares Climb 97% But Its Business Is Yet to Catch Up
TRBR
CA$0.83
TRUBAR
7D
9.2%
1Y
31.7%
GTII
CA$10.25
Green Thumb Industries
7D
-10.5%
1Y
-27.0%
TSND
CA$1.07
TerrAscend
7D
-10.1%
1Y
-32.7%
HLS
CA$5.59
HLS Therapeutics
7D
2.6%
1Y
71.5%
GRIN
CA$0.66
Grown Rogue International
7D
11.9%
1Y
-25.0%
QNTM
CA$23.80
Quantum BioPharma
7D
21.4%
1Y
339.9%